Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and …
Z DeFilipp, RF Duarte, JA Snowden… - Bone marrow …, 2017 - nature.com
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the
risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors …
risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors …
Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues
R Bhatnagar, NM Dixit, EH Yang… - Frontiers in …, 2022 - frontiersin.org
Atherosclerotic cardiovascular disease is a growing threat among cancer patients. Not
surprisingly, cancer-targeting therapies have been linked to metabolic dysregulation …
surprisingly, cancer-targeting therapies have been linked to metabolic dysregulation …
[HTML][HTML] Metabolic syndrome and cardiovascular disease after hematopoietic cell transplantation: screening and preventive practice recommendations from the …
Z DeFilipp, RF Duarte, JA Snowden, NS Majhail… - Biology of Blood and …, 2016 - Elsevier
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the
risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term …
risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term …
Cardiovascular disease following hematopoietic stem cell transplantation: pathogenesis, detection, and the cardioprotective role of aerobic training
Advances in hematopoietic cell transplantation (HCT) techniques and supportive care
strategies have led to dramatic improvements in relapse mortality in patients with high-risk …
strategies have led to dramatic improvements in relapse mortality in patients with high-risk …
Cancer survivors: an expanding population with an increased cardiometabolic risk
F Felicetti, N Fortunati, E Brignardello - Diabetes research and clinical …, 2018 - Elsevier
In the last decades the survival rate of patients diagnosed with cancer-both in childhood and
adulthood-significantly improved, leading to a growing number of cancer survivors (CS) …
adulthood-significantly improved, leading to a growing number of cancer survivors (CS) …
Long‐term follow‐up of hematopoietic stem cell transplant survivors: a focus on screening, monitoring, and therapeutics
IM Saunders, M Tan, D Koura… - … : The Journal of Human …, 2020 - Wiley Online Library
Annually,~ 50,000 patients undergo hematopoietic stem cell transplantation (HCT)
worldwide with almost 22,000 of these patients receiving HCT in the United States. HCT is a …
worldwide with almost 22,000 of these patients receiving HCT in the United States. HCT is a …
Optimal delivery of follow-up care after allogeneic hematopoietic stem-cell transplant: improving patient outcomes with a multidisciplinary approach
L Giaccone, F Felicetti, S Butera, D Faraci… - Journal of blood …, 2020 - Taylor & Francis
The increasing indications for allogeneic stem-cell transplant in patients with hematologic
malignancies and non-malignant diseases combined with improved clinical outcomes have …
malignancies and non-malignant diseases combined with improved clinical outcomes have …
Metabolic reprogramming—a new era how to prevent and treat graft versus host disease after allogeneic hematopoietic stem cell transplantation has begun
R Kumari, S Palaniyandi, GC Hildebrandt - Frontiers in Pharmacology, 2020 - frontiersin.org
Allogeneic hematopoietic stem cell transplantation (HSCT) is the solitary therapeutic therapy
for many types of hematological cancers. The benefits of this procedure are challenged by …
for many types of hematological cancers. The benefits of this procedure are challenged by …
High Throughput analysis reveals changes in gut microbiota and specific fecal metabolomic signature in hematopoietic stem cell transplant patients
There is mounting evidence for the emerging role of gut microbiota (GM) and its metabolites
in profoundly impacting allogenic hematopoietic stem cell transplantation (allo-HSCT) and …
in profoundly impacting allogenic hematopoietic stem cell transplantation (allo-HSCT) and …
Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
Y Lu, X Ma, J Pan, R Ma, Y Jiang - Lipids in Health and Disease, 2022 - Springer
Dyslipidemia is one of the complications after allogeneic hematopoietic stem cell
transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia …
transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia …